CPC C07K 16/2863 (2013.01) [C07K 16/00 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/32 (2013.01); C07K 16/40 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/60 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/71 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01)] | 8 Claims |
1. A bispecific-Fc molecule (Bi-Fc) monomer which mediates cytolysis of a cancer cell by a T cell, wherein the Bi-Fc comprises a polypeptide chain comprising an amino acid sequence having the following formula: V1-L1-V2-L2-V3-L3-V4-L4-Fc or Fc-L4-V1-L1-V2-L2-V3-L3-V4; wherein two of V1, V2, V3, and V4 are heavy chain variable (VH) regions and the other two are light chain variable (VL) regions; wherein one VH region and one VL region binds CD3 epsilon on a T cell and one VH region and one VL region binds HER2 on the cancer cell; wherein Fc is a human IgG Fc polypeptide chain; wherein L1, L2, L3, and L4 are linkers; wherein L4 can be present or absent; and wherein the Bi-Fc monomer comprises a single chain anti-HER2/CD3 epsilon antibody comprising the amino acid sequence of SEQ ID NO: 9.
|